Arch Biopartners Stock Probability of Future Stock Price Finishing Over 4.66
| ARCH Stock | CAD 1.96 0.04 2.08% |
Arch |
Arch Biopartners Target Price Odds to finish over 4.66
The tendency of Arch Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over C$ 4.66 or more in 90 days |
| 1.96 | 90 days | 4.66 | close to zero percent |
Based on a normal probability distribution, the odds of Arch Biopartners to move over C$ 4.66 or more in 90 days from now is close to zero percent (This Arch Biopartners probability density function shows the probability of Arch Stock to fall within a particular range of prices over 90 days) . Probability of Arch Biopartners price to stay between its current price of C$ 1.96 and C$ 4.66 at the end of the 90-day period is about 22.66 .
Assuming the 90 days trading horizon Arch Biopartners has a beta of 0.25. This suggests as returns on the market go up, Arch Biopartners average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Arch Biopartners will be expected to be much smaller as well. Additionally Arch Biopartners has an alpha of 0.4962, implying that it can generate a 0.5 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Arch Biopartners Price Density |
| Price |
Predictive Modules for Arch Biopartners
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Arch Biopartners. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Arch Biopartners Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Arch Biopartners is not an exception. The market had few large corrections towards the Arch Biopartners' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Arch Biopartners, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Arch Biopartners within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.50 | |
β | Beta against Dow Jones | 0.25 | |
σ | Overall volatility | 0.20 | |
Ir | Information ratio | 0.15 |
Arch Biopartners Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Arch Biopartners for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Arch Biopartners can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Arch Biopartners may become a speculative penny stock | |
| Arch Biopartners has accumulated 5.02 M in total debt. Arch Biopartners has a current ratio of 0.31, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.98 M. Net Loss for the year was (3.33 M) with loss before overhead, payroll, taxes, and interest of (502.88 K). | |
| Arch Biopartners has accumulated about 72.82 K in cash with (234.07 K) of positive cash flow from operations. | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - Yahoo Finance |
Arch Biopartners Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Arch Stock often depends not only on the future outlook of the current and potential Arch Biopartners' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Arch Biopartners' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62.5 M | |
| Cash And Short Term Investments | 831.3 K |
Arch Biopartners Technical Analysis
Arch Biopartners' future price can be derived by breaking down and analyzing its technical indicators over time. Arch Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Arch Biopartners. In general, you should focus on analyzing Arch Stock price patterns and their correlations with different microeconomic environments and drivers.
Arch Biopartners Predictive Forecast Models
Arch Biopartners' time-series forecasting models is one of many Arch Biopartners' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Arch Biopartners' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Arch Biopartners
Checking the ongoing alerts about Arch Biopartners for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Arch Biopartners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Arch Biopartners may become a speculative penny stock | |
| Arch Biopartners has accumulated 5.02 M in total debt. Arch Biopartners has a current ratio of 0.31, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.98 M. Net Loss for the year was (3.33 M) with loss before overhead, payroll, taxes, and interest of (502.88 K). | |
| Arch Biopartners has accumulated about 72.82 K in cash with (234.07 K) of positive cash flow from operations. | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - Yahoo Finance |
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.